Search Results

Showing results 11-21 of 31 for 'Clinical trials'

  • weizmann-views-moshe-oren-tn
    Using Basic Science to Advance Cancer Research

    Prof. Moshe Oren has spent decades studying the p53 gene, which plays a key role in keeping healthy cells from turning cancerous. His basic research has inspired other scientists to build on his findings, potentially leading to p53-based cancer treatments. As head of the Moross Integrated Cancer Center, Prof. Oren's knowledge will be more valuable than ever.

  • stop-prostate-cancer-tn
    Revolutionary Therapy for Prostate Cancer Coming to Europe

    Tookad, the prostate cancer treatment developed by Profs. Avigdor Scherz and Yoram Salomon, ""now is undergoing advanced trials in Israel and Europe,"" says Israel21c. Already approved for use in Mexico and on the verge of being more widely available, Tookad's efficacy for other cancers is now being tested in collaboration with Oxford University and Memorial Sloan Kettering.

  • header-thumbnail
    Immunotherapy: Cancer Treatment Based on Weizmann Research is Saving Lives

    Weizmann Institute basic research is, yet again, behind the headlines: a new blood cancer therapy that uses one's own immune system to defeat the disease is stunning clinicians and giving patients hope. Trials in the U.S. have had amazing results, with critically ill leukemia patients now in remission. The breakthrough is based on decades of research by Weizmann's Prof. Zelig Eshhar, who is now working to adapt his method to other forms of cancer.

  • cancer-cells-tn
    Weizmann-Developed Drug May Be Speedy Prostate Cancer Cure, Studies Show

    As <em>The Times of Israel</em> reports, ""In a trial, a photosynthesis-based therapy eliminates cancer in over 80% of patients – and could be used to attack other cancers, too."" That therapy – developed at the Weizmann Institute – involves administering a drug, then zapping it with light, basically starving the tumor to death … and all without side effects.

  • sela-michael-tn
    One Patent, Three Drugs

    Many years ago, Prof. Michael Sela and colleagues found that antibodies inhibiting EGFR, a receptor that plays a role in cancer, have a synergistic anti-cancer effect when used with chemotherapy. That discovery has now led to three cancer-treating drugs: Erbitux<sup>®</sup>, Vectibix<sup>®</sup>, and, most recently, Portrazza<sup>™</sup>, just FDA approved for a form of lung cancer.

  • Andromeda Biotech Reports that a Drug for Type 1 Diabetes, Developed by Prof. Irun Cohen of the Weizmann Institute, Meets Primary and Secondary Goals of Phase III Clinical Trials

    Patients with Type 1 diabetes who were treated with DiaPep277® in clinical trials saw benefits. Weizmann's Prof. Irun Cohen developed the novel drug.

  • bladder-cancer-tn
    A New Noninvasive Monitoring Test for Bladder Cancer

    Two Weizmann PhDs are behind Nucleix, an Israeli company that has designed a simple test for monitoring bladder cancer – the most expensive cancer to treat over a patient's lifetime. Called ""Bladder EpiCheck,"" the method is in advanced clinical trials in The Netherlands, Germany, Spain, and Israel, reports <em>Israel21c</em> – and is heading for the U.S.

  • prof-michel-revel-tn
    Unraveling the Mysteries of Science and Disease

    Weizmann Prof. Emeritus Michel Revel's long, brilliant career includes co-developing Copaxone® and Rebif®, two of the world's leading MS drugs. At 75, rather than retire, he's still breaking ground: his new biotech firm is developing applications for human embryonic stem cells, aiming to better treat – and cure – diabetes and other diseases.

  • eye-image-tn
    Using Young Cells to Fight Age-Related Macular Degeneration

    Israeli company Cell Cure Neurosciences is conducting clinical trials on a stem-cell-based treatment for age-related macular degeneration (AMD), reports Israel21c. The firm's CEO, Charles Irving, conducted his doctoral research in chemistry at Weizmann. Currently, treatment options for AMD – a major cause of blindness in adults – are limited.